You are on page 1of 41

Page.

FORMULATION AND EVELUATION OF SUSTAINED RELEASE


TABLETS OF IBUPROFEN

A project report submitted

In partial fulfillment of the requirement


For the award of the degree of

BACHELOR OF PHARMACY

JUNAID MALIK
EnrollmentNo-131576

Under the guidance of


Dr RITU GUPTA

DEPARTMENT OF PHARMACEUTICS
INVERTIS INSTITUTE OF PHARMACY
INVERTIS UNIVERSITY
BAREILLY-LUCKNOW HIGHWAY, NH-24, BAREILLY, U.P

2016---2017
Page.2

CERTIFICATE

This is to certify that the project report entitled Formulation and Evaluation of
Sustained Release Tablets of Ibuprofen is being submitted by Junaid Malik
bearing a Enrollment no. 131559 in partial fulfillment of the requirement for the
award of the Degree of Bachelor of Pharmacy, for the elective subject Novel
Drug Delivery System at Invertis Institute of Pharmacy, Invertis University,
Bareilly. The Institute wishes him all the success in life.
.

Supervisor Head of Department


Dr .Ritu Gupta Mr. Ajit Yadav
Associate professor Associate professor
Page.3

ACKNOWLEDGEMENT

It is said that accomplishments must be credited to those who had put up

The foundations of the particular chore. In a work of this magnitude, it was natural to solicit

guidance, help and co-operation from many people and I like to acknowledge all those who

generously provided their time and expertise to maintain the quality of work.

First and foremost I express my profound gratitude and venerable regards to my guide

Dr .Ritu Gupta as a teacher she has always strived to inculcate the scientific attitude in me. I

am thankful to her for his guidance, vital encouragement, incisive criticism and dynamic

assistance. She was always present for me, whenever I needed him and I cherish the amount of

freedom I have enjoyed during this tenure under him.

I would like to express my sincere regards to Mr. Ajit yadav Head of the Department,

who is guardian figure to me. He supported me in my research and instilled confidence to reach

greater heights in my life and Mr. Vipin Agrwal for his help, fruitful knowledge, suggestions

and advice for the work.

This task would have been fruitless without the blessing, support, encouragement and

inspiration o f Mr.Himanshu Joshi and Mr.Shashank Chaturvedi. Here I pay tributes to my

parents for lifting me up in my life. I sincerely thank them for their love, trust, patience &

support without which I would have failed to stand where I am standing today. My deepest sense

of gratitude towards my father, Mr. Intzar Ahmad and my mother Mrs. Shabnam Ahmad who

has always motivated and contributed towards the pursuance of my studies, without worrying

about all odds. My sincere thanks to my brother Azam malik who has always played a role of a

wise advisor and he really deserves heartfelt thanks for her wishes, love and support.
Page.4

At this moment I really shall not forget my sister Arshi Malik who always dreamed of me

reaching to this level. I would really thank all the rest of my family who have directly and

indirectly helped me to achieve my goals.

I am grateful to Dr .Umesh Gautam chancellor of Invertis University for his words of

encouragement and timely support

I express my indebtedness to our vice chancellor prof. Jadish Rai for his help and

cooperation throughout my project work.

I express my sincere thanks to Dr. Y.D.S. Arya for his kindness, helpfulness and

motivating thoughts.

I really feel short of words when it comes in expressing my deep sense of gratitude

towards, Kunwar Pal Singh, Bharat Singh, Keshav Sharma, and Parvez, for all their

cooperation, support and making me believe that I am capable of doing even better.

Words fail to express my gratitude towards our M.pharm seniors Mr. Ashish Gangwar,

Mr. Akhil Chaudhary, and Ms. Sumbul Naaz helped me to achieve my targets.

Date:

Place: Junaid Malik


Page.5

CONTENTS

CHAPTER NO. TITEL NO. PAGE NO.

I 6-16
NITRODUCTION

II 17-18
REVIEW OF LITERATURE

III PRE FORMULATION 19-22

IV FORMULATION 23-24

V EVALUATION 25-36

VI RESULT AND 37-39


DISCUSSION
Page.6

Chapter I
Introduction

INTRODUCTION

Oral route is the most oldest and convenient route for the administration of
therapeutic agents because of low cost of therapy and ease of administration
leads to higher level of patient compliance. Approximately 50% of the drug
delivery systems available in the market are oral drug delivery systems and
Page.7

historically too, oral drug administration has been the predominant route for
drug delivery. It does not pose the sterility problem and minimal risk of
damage at the site of administration.

During the past three decades, numerous oral delivery systems have been
developed to act as drug reservoirs from which the active substance can be
released over a defined period of time at a predetermined and controlled
rate. The oral controlled release formulation have been developed for those
drug that are easily absorbed from the gastrointestinal tract (GIT) and have a
short half-life are eliminated quickly from the blood circulation. As these will
release the drug slowly into the GIT and maintain a constant drug
concentration in the plasma for a longer period of time.

The sustained release, sustained action, prolonged action, controlled release,


extended action, timed release, depot and respiratory dosage forms are
terms used to identify drug delivery system that are designed to achieve a
prolonged therapeutic effect by continuously releasing medication over an
extended period of time after administration of a single dose

Extended release formulation is an important program for new drug research


and development to meet several unmet clinical needs. There are several
reasons for attractiveness of these dosage forms viz. provides increase
bioavailability of drug product, reduction in the frequency of administration
to prolong duration of effective blood levels, Reduces the fluctuation of peak
trough concentration and
side effects and possibly improves the specific distribution of the drug.
Extended release drug delivery system achieves a slow release of the drug
over an extended period of time or the drug is absorbed over a longer period
of time. Extended release dosage form initially releases an adequate amount
of drug to bring about the necessary blood concentration (loading dose, DL)
for the desired therapeutic response and therefore, further amount of drug is
Page.8

released at a controlled rate (maintenance dose, DM) to maintain the said


blood levels for some desirable period of time.

Definition
Extended release means the pill is formulated so that the drug is released
slowly over time. This has the advantage of taking pills less often. Also
means that there may be fewer side effects as the levels of the of drug in the
body are more consistent in extended release formulations.

Advantages
Sustained drug delivery: As mentioned earlier, drug absorption from oral controlled release (CR)
dosage forms is often limited by the short GRT available for absorption. However, HBS type
dosage forms can retain in the stomach for several hours and therefore, significantly prolong the
GRT of numerous drugs. These special dosage forms are light, relatively large in size, and do not
easily pass through pylorus, which has an opening of approx. 0.1 1.9 cms. Site specific drug
delivery a floating dosage form is a feasible approach especially for drugs which have limited
absorption sites in upper small intestine. The controlled, slow delivery of drug to the stomach
provides sufficient local therapeutic levels and limits the systemic exposure to the drug. This
reduces side effects that are caused by the drug in the blood circulation. In addition the prolonged
gastric availability from a site directed delivery system may also reduce the dosing frequency.
The eradication of Helicobacter pylori requires the administration of various medicaments
several times a day, which often results in poor patient compliance. More reliable therapy can be
achieved by using GRDDS. Floating alginate beads have been used for the sustained release of
Amoxycillin trihydrate. Thus, it can be expected that the topical delivery of antibiotic through a
FDDS may result in complete removal of the organisms in the fundal area due to bactericidal
drug levels being reached in this area, and might lead to better treatment of peptic ulcer.

Pharmacokinetic advantages
As sustained release systems, floating dosage forms offer various potential advantages. Drugs
that have poor bioavailability because their absorption is limited to upper GI tract can be
delivered efficiently thereby maximizing their absorption and improving their absolute
Page.9

bioavailability. Floating dosage forms with SR characteristics can also be expected to reduce the
variability in transit performance. In addition, it might provide a beneficial strategy for gastric
and duodenal cancer treatment.

Disadvantages

1. The major disadvantage of floating system is requirement of a sufficient high level of fluids in
the stomach for the drug delivery to float. However this limitation can be overcome by coating
the dosage form with the help of Bioadhesive polymers that easily adhere to the mucosal lining
of the stomach.
2. Floating system is not feasible for those drugs that have solubility or stability problem in
gastric fluids.
3. The dosage form should be administered with a minimum of glass full of water (200-250 ml).
4. The drugs, which are absorbed throughout gastro-intestinal tract, which undergo first pass
metabolism (Nifedipine, propranolol etc.), are not desirable candidate.
5. Some drugs present in the floating system causes irritation to gastric mucosa.

Classification of oral sustained/controlled release systems


Diffusion controlled Systems

Reservoir devices:
A core of drug (reservoir) surrounded by a polymeric membrane characterizes them. The nature
of the membrane determines the rate of drug release. The characteristics of reservoir diffusion
systems are
1. Zero order drug release is possible.
2. The release rate is dependent on the type of polymer.
3. High molecular weight compounds are difficult to deliver through the device.

Matrix devices:
It consists of drug dispersed homogenously in a matrix. The characteristics of matrix diffusion
systems are
Page.10

1. Zero order release cannot be obtained.


2. Easy to produce than reservoir devices.
3. High molecular weight compounds are delivered through the device.

Dissolution controlled systems

Matrix dissolution controlled systems:


Aqueous dispersions, congealing, spherical agglomeration, etc. can be used.

Encapsulation dissolution controlled systems:

Particles, seeds, granules can be coated by techniques such as microencapsulation.

Diffusion and dissolution controlled systems:

In a bioerodible matrix, the drug is homogenously dispersed in a matrix and it is released either
by swelling controlled mechanism or by hydrolysis or by enzymatic attack.

Sustained release matrix tablets:

One of the least complicated approaches to the manufacture of sustained release dosage forms is
the direct compression of drug, release retardant, and additives to form a tablet in which drug is
embedded in a matrix core of retardant. Alternatively drug retardant blend may be granulated
prior to compression. Such tablets are called as matrix tablets. Three classes of release retarding
materials are used for the formulation of matrix tablets. They include

1. Insoluble or skeleton matrices


2. Water insoluble, erodable matrices
3. Hydrophilicmatrices.
Page.11

Mechanism of drug release:

On exposure to aqueous fluid, hydrophilic matrices take up water, and polymer starts hydrating
to form a gel layer. An initial burst of soluble drug may occur due to surface leaching when a
matrix containing a swellable glassy polymer comes in contact with an aqueous medium, there is
an abrupt change from a glassy to a rubbery state which is associated with swelling process with
time, water infiltrator deep into the case increasing the thickness by the gel layer. Concomitantly
the outer layer becomes fully hydrated and states dissolving or eroding. When water reaches the
center of the system and the concentration of drug fells below the solubility value, the release
rate of drug begins to reduce. At the same time, an increase in thickness of the barrier layer with
time increases the diffusion path length, reducing the rate of drug release. Drug release kinetic
associated with these gel layer dynamic, range initially from Fickian to annomalous (Non
Fickian) and subsequently from quasi Constant ( near Zero order ) to constant. In general, two
major factors control the drug release from swelling controlled matrix system. They include
many processes given below.

1. The rate of aqueous medium infiltration into the matrix, followed by a relaxation process
(hydration, gelatin or swelling).

2. The rate of matrix erosion

As a result of these simultaneous processes, two front are evident, a swelling front, where the
polymer get hydrated, and an eroding front. The distance between these two fronts are called
diffusion layer thickness. Diffusion layer thickness depends on the selective rate at which the
swelling and eroding fronts move in relation to each other. If the polymer gets slowly, solvent
can penetrate deep into the glassy matrix the dissolving the drug; there for gel layer thickness
and it stability are council in controlling drug release. Swelling of HPMC matrix tablet was
higher for higher a molecular weight. They attributed this to the large hydrodynamic volume
occupied by higher molecular weight chain when hydrated. As the polymer chain becomes more
hydrated and the gel becomes more dilute, the disentanglement concentration may be reached
Page.12

that is the critical polymer concentration below which the polymer chain disentangle and
detached from gelled matrix.

DRUG PROFILE

DESCRIPTION
Page.13

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate


pain, and helps to relieve symptoms of arthritis (osteoarthritis, rheumatoid arthritis, or juvenile
arthritis), such as inflammation, swelling, stiffness, and joint pain

Chemical name: 2 (4-isobutyl phenyl) propanoic acid,

Structure:

Molecular formula: C13H8O2

Molecular weight: 206.29 g/mol

Melting point: 76 0C

Boiling point: 319.6 11.0 0C

Half life: Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion of
ibuprofen is virtually complete 24 hours after the last dose. The serum half-life is 1.8 to 2.0
hours.

Ultra violet:
Bioavailability
Page.14

Ibuprofen is rapidly absorbed, and both peak plasma concentrations and maximal analgesic
onset are achieved within 1.5-2 hours of oral administration. The first is a
sodium ibuprofen formulation containing 256 mg of ibuprofen sodium dehydrate per tablet
(equivalent to 200 mg ibuprofen acid)

Volume of distribution
Protein binding is saturable and at concentrations >20 g/mL binding is non-linear. Based on
oral dosing data there is an age- or fever- related change in volume of distribution for ibuprofen.
Febrile children <11 years old have a volume of approximately 0.2 L/kg while adults have a
volume of approximately 0.12 L/kg.

Mechanism of action: Ibuprofen is a non-selective inhibitor of an enzyme called


cyclooxygenase (COX), which is required for the synthesis of prostaglandins via the arachidonic
acid pathway. COX is needed to convert arachidonic acid to prostaglandin H2 (PGH2) in the
body

Fig 1.mechanism of Ibuprofen


Ibuprofen dosing information

Usual Adult Dose for Dysmenorrheal:


Page.15

200 to 400 mg orally every 4 to 6 hours as needed.

Usual Adult Dose for Osteoarthritis:

Initial dose: 400 to 800 mg orally every 6 to 8 hours. Maintenance dose: May be increased to a
maximum daily dose of 3200 mg based on patient response and tolerance.

Usual Adult Dose for Rheumatoid Arthritis:

Initial dose: 400 to 800 mg orally every 6 to 8 hours. Maintenance dose: May be increased to a
maximum daily dose of 3200 mg based on patient response and tolerance.

Usual Adult Dose for Headache:

Study (n=34) - Prevention of Electroconvulsive therapy (ECT)-induced headache. 600 mg orally


90 minutes prior to the initial ECT session

Usual Adult Dose for Pain:

Oral: Mild to moderate pain: 200 to 400 mg orally every 4 to 6 hours as needed. Doses greater
than 400 mg have not been proven to provide greater efficacy. IV: (Patients should be well
hydrated before IV ibuprofen administration) Pain: 400 to 800 mg intravenously over 30 minutes
every 6 hours as needed.

Usual Adult Dose for Fever:

Oral: 200 to 400 mg orally every 4 to 6 hours as needed. IV: (Patients should be well hydrated
before IV ibuprofen administration) Fever: Initial: 400 mg intravenously over 30 minutes
Maintenance: 400 mg every 4 to 6 hours or 100 to 200 mg every 4 hours as needed.

Usual Pediatric Dose for Fever:

Greater than 6 months 12years, 5 mg/kg/dose for temperature less than 102.5 degrees F (39.2
degrees C) orally every 6 to 8 hours as needed.10 mg/kg/ dose for temperature greater than or
equal to 102.5 degrees F (39.2 degrees C) orally every 6 to 8 hours as needed. The recommended
Page.16

maximum daily dose is 40 mg/kg. OTC pediatric labeling (analgesic, antipyretic): 6 months to
11 years: 7.5 mg/kg/dose every 6 to 8 hours; Maximum daily dose: 30 mg/kg

Usual Pediatric Dose for Pain:

Infants and Children: 4 to 10 mg/kg orally every 6 to 8 hours as needed. The recommended
maximum daily dose is 40 mg/kg. OTC pediatric labeling (analgesic, antipyretic): 6 months to 11
years: 7.5 mg/kg/dose every 6 to 8 hours; Maximum daily dose: 30 mg/kg

Usual Pediatric Dose for Rheumatoid Arthritis:

6 months to 12 years: Usual: 30 to 40 mg/kg/day in 3 to 4 divided doses; start at lower end of


dosing range and titrate; patients with milder disease may be treated with 20 mg/kg/day; doses
greater than 40 mg/kg/day may increase risk of serious adverse effects; doses greater than 50
mg/kg/day have not been studied and are not recommended. Maximum dose: 2.4 g/day

CHAPTER II
REVIEW OF
Page.17

LITERATURE

REVIEW OF LITERATURE

1. Kamalakkannan.V, et al (2015) developed sustained release matrix tablets Tramadol


Hydrochloride are using gum kondagogu as a natural polymer.

2. Katakam P, et al (2014) formulated and evaluated sustained release venlafaxine tablets using
hydrophilic-hydrophobic polymer combinations by melt granulation.

3. Nagendrakumar D.et al (2013) formulated of sustained release matrix tablets furosemide


using natural and synthetic polymers.

4. Mote. P.B. et al, (2013) formulated and evaluated Sustained Release Matrix Tablets Of Anti-
Asthmatic Agent Using Various Polymers.
Page.18

5. Asija. R et al.(2012) formulated and evaluated Diclofenac sodium sustained release tablets
using melt granulation technique.
6. Kalvimoorthi.V, et al. (2011) formulated development and evaluated aspirin delayed release
tablets.
7. Mohamed. B.S et al.(2011) prepared and evaluated silymarin controlled release tablets
prepares using natural gums.
8. Shaikh.A.C et al (2011) formulated and evaluated Sustained Release Tablets Aceclofenac
using hydrophilic matrix system.

9. Deore R.K, et al (2010) perpetrated and evaluated of Sustained Release Matrix tablets
Tramadol Hydrochloride Using Glyceryl Palmitostearate.

10. Iqbal. K, et al (2012) prepared and evaluated Controlled Release Tablets Containing
Mefenamic acid.

CHAPTER III
Page.19

PRE FORMULATION

PRE FORMULATION

UV SPECTROSCOPY:
An U.V spectrophotometric method based on the measurement of absorbance at 245 nm in
phosphate buffer oh pH 5.8 was used for the estimation of paracetamol. The method obeyed
Beers law in the concentration range 0 - 10 g/ml.
Page.20

Fig 2.Calibration curve

Angle of repose:
The angle of repose of powdered gum was determined by the funnel method. The accurately
weighed granules were taken in a funnel. The height of the funnel was adjusted in such a way
that the tip of the funnel just touched the apex of the heap of granules. The granules were
allowed to flow through the funnel freely onto the surface. The diameters of powder cone was
measured and angle of repose was calculated using the equation.
Page.21

=tan1(h/r )

Bulk density
Both bulk density (BD) and tapped density (TBD) were determined. A quantity of 2 gm of
powder from each formula, previously lightly shaken to break any agglomerates formed, was
introduced into a 10 ml measuring cylinder. After the initial volume was observed, the cylinder
was allowed to fall under its own weight on to a hard surface form the height of 2.5 cm at 2
second intervals. The tapping was continued until no further change in volume was noted. LBD
and TBD were calculated using the formulas.
BD = Weight of the powder/volume of the packing
TBD = Weight of the powder/tapped volume of the packing

Compressibility index /Carrs index


The flow of property was also determined by measuring the compressibility index. It is an
important measure that can be obtained from the bulk and tapped densities. According to the
theory, the less compressible materials are more flowable. A material having values of less than
20 to 30% is defined as the free flowing martial, based on the apparent bulk density and tapped
density, the drug was determined by using the formulas.9
density
comperessibility index=bulk 100
tap density
Page.22

Table1.precompression parameters of Aspirin floating tablets,

S Test F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
N
o
1 Bulk 0.62 065 0.60 0.62 0.64 0.69 0.61 0.62 0.62 0.60
density
(gm/ml)

2 Tapped 0.87 0.87 0.86 0.80 0.873 0.87 0.89 0.85 0.876 0.85
density
(gm/ml)

3 Care 28.73 29.83 28.80 30.25 29.98 30.35 31.23 29.98 28.80 29.8
index 0
4 Angle 25 25 25 24 26 25 26 28 25 25
of .2
repose .24 .34 .45 .45 .56 .56 .30 .45
(degree) 5 .24
Page.23

CHAPTER IV
FORMULATION

FORMULATION

Materials and Methods


Ibuprofen CDH New Delhi, CMC CDH New Delhi, Magnesium sterate CDH New Delhi, Talc
CDH New Delhi, HPMC CDH New Delhi, Microcrystalline cellulose CDH New Delhi, P V P
CDH New Delhi,
Page.24

Table2: of Formulation
Sr. Name of Amount (gm/tablet)
No. Ingredient
Formulation F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Code
1 Ibuprofen 200 200 200 200 200 200 200 200 200 200

2 CMC 50 75 100 - 50 75 60 70 100 50


3 HPMC - - - 100 50 25 25 - 15 35
4 PVP 9.5 9.5 9.5 9.5 9.5 9.5 9.5 9.5 9.5 9.5
5 Microcrystallin 235 210 185 185 185 185 200 215 170 200
e cellulose
6 Magnesium 10 10 10 10 10 10 10 10 10 10
sterate
7 Talc 5 5 5 5 5 5 5 5 5 5
Page.25

CHAPTER V
EVALUATION

EVALUATION

1. Weight variation test


The weight variation test for given tablet was successfully done
Formula
% deviation or % weight deviation =
Page.26

Indivsual weight Avrage weight


100
Avrage weight

Procedure
Taken 20 tablet to perform weight variation test.
Weighed 20 tablet collectively with the aid of electronic balance.
Calculated the average weight of 20 tablets collectively.
Now weighed the individual tablet by using electronic balance.
Calculation of deviation was done by using mentioned formula.

Table 3. Weight variation test for F1


S No Individual weight Average weight % Deviation Inference
1 510 500 2
2 520 500 4
3 490 500 -2
4 490 500 -2
5 495 500 -1
6 495 500 -1
7 480 500 -4
Page.27

8 480 500 -4
9 510 500 2
10 510 500 2
11 510 500 2
12 515 500 3
13 520 500 4
14 480 500 -4
15 490 500 -2
16 490 500 -2
17 495 500 -1
18 480 500 -4

19 480 500 -4

20 525 500 5

Table 4. Weight variation test for F2

S No Individual weight Average weight % Deviation Inference


1 525 500 5 Fail
2 530 500 6 Fail
3 530 500 6 Fail
4 531 500 6.2 Fail
5 526 500 5.2 Fail
6 527 500 5.4 Fail
7 529 500 5.8 Fail
8 493 500 -1.4 Pass
9 493 500 -1.4 Pass
Page.28

10 482 500 -3.6 Pass


11 472 500 -5.6 Fail
12 472 500 -5.6 Fail
13 493 500 -1.4 Pass
14 293 500 -1.4 Pass
15 492 500 -1.6 Pass
16 492 500 -1.6 Pass
17 499 500 -0.2 Pass
18 498 500 -0.4 Pass
19 499 500 -0.2 Pass
20 532 500 6.4 Fail

Table5. Weight variation test for F3

S No Individual weight Average weight % Deviation Inference


1 510 500 2 Pass
2 520 500 4 Pass
3 490 500 -2 Pass
4 490 500 -2 Pass
5 495 500 -1 Pass
6 495 500 -1 Pass
7 480 500 -4 Pass
8 480 500 -4 Pass
9 510 500 2 Pass
10 510 500 2 Pass
11 525 500 5 Fail
12 530 500 6 Fail
13 530 500 6 Fail
Page.29

14 531 500 6.2 Fail


15 526 500 5.2 Fail
16 527 500 5.4 Fail
17 529 500 5.8 Fail
18 493 500 -1.4 Pass
19 493 500 -1.4 Pass
20 482 500 -3.6 pass

Table 7. Weight variation test for F4

S No Individual weight Average weight % Deviation Inference


1 510 500 2 Pass
2 510 500 2 Pass
3 515 500 3 Pass
4 520 500 4 Pass
5 480 500 -4 Fail
6 490 500 -2 Pass
7 490 500 -2 Pass
8 495 500 -1 Pass
9 480 500 -4 Fail
10 480 500 -4 Fail
11 472 500 -5.6 Fail
12 472 500 -5.6 Fail
13 493 500 -1.4 Pass
14 293 500 -1.4 Pass
15 492 500 -1.6 Pass
16 492 500 -1.6 Pass
17 499 500 -0.2 Pass
Page.30

18 498 500 -0.4 Pass


19 499 500 -0.2 Pass
20 532 500 6.4 Fail

Table 8.Weight variation test for F5

S No Individual weight Average weight % Deviation Inference


1 510 500 2 Pass
2 520 500 4 Pass
3 490 500 -2 Pass
4 490 500 -2 Pass
5 495 500 -1 Pass
6 495 500 -1 Pass
7 480 500 -4 Fail
8 480 500 -4 Fail
9 510 500 2 Pass
10 510 500 2 Pass
11 510 500 2 Pass
12 515 500 3 Pass
13 520 500 4 Pass
14 480 500 -4 Fail
15 490 500 -2 Pass
16 490 500 -2 Pass
17 495 500 -1 Pass
18 480 500 -4 Fail
Page.31

19 480 500 -4 Fail


20 525 500 5 Fail

Table 9.weight variation test for F6


S No Individual weight Average weight % Deviation Inference
1 525 500 5 Fail
2 530 500 6 Fail
3 530 500 6 Fail
4 531 500 6.2 Fail
5 526 500 5.2 Fail
6 527 500 5.4 Fail
7 529 500 5.8 Pass
8 493 500 -1.4 Pass
9 493 500 -1.4 Fail
10 482 500 -3.6 Fail
11 472 500 -5.6 Pass
12 472 500 -5.6 Fail
13 493 500 -1.4 Fail
14 293 500 -1.4 Pass
15 492 500 -1.6 Pass
16 492 500 -1.6 Fail
17 499 500 -0.2 Fail
18 498 500 -0.4 Fail
Page.32

19 499 500 -0.2 Pass


20 532 500 6.4 Pass

2. Friability test
Procedure
Roche friabilatar A number and deducted tablets (usually 6mg) are placed in tumbling apparatus
made the plastic that revolves at 25 rpm and drops the tablets to distance of 6 niche with each
revaluation normally the tablet are subjected to free for 100 revolution or 10 minutes. The tablets
are then deducted and are weighed the friability is calculated by formula. 25 rpm for 25 min.

Inetial weightFina l weight


Freability= X 100
Initial weight

Table10. Friability
S No Formulation Code Friability %
1 F1 0.8
2 F2 1.0
3 F3 1.2
4 F4 1.0
5 F5 0.8
6 F6 1.1
7 F7 1.2
8 F8 1.3
9 F9 1.0
10 F10 1.1

3. Hardness Test
In hardness test we Monsanto and Pfizer
We put the individual tablet in to the Monsanto and Pfizer,
We repeated the process 6 trims
Apply the force and when the tablet starts braking the records the reading from the points
Page.33

PFIZER TESTER

Hardness which is now more appropriately called crushing strength determinations are made
during tablet production and are used to determine the need for pressure adjustment on tablet
machine.

The strength of a tablet can be determined by breaking it between second and third fingers with
the thumb acting as a fulcrum. If there is a click sound, the tablet is deemed to have acceptance
strength.

If the tablet is too hard, it may not disintegrate in the required period of time to meet the
dissolution specifications; if it is too soft, it may not be able to withstand the handling during
subsequent processing such as coating or packaging and shipping operations.
Page.34

Fig3. Pfizer tester of tablets

Table 11. For Hardness


S No Formulation No Hardness kg/cm
1 F1 6
2 F2 7
3 F3 9
4 F4 8
5 F5 5
6 F6 6
7 F7 6
8 F8 8
9 F9 9
10 F10 6

4. Dissolution Test
Procedure
Placed the 900 ml of water which should be free from dissolution air and warm set up to
37 0C
Placed the tablets in the basket and set the apparatus
Start the motor and adjust rotation speed of 50 rpm
Now take the reading after 5 min 10, 15, 30, and 45 minutes by diluting 1 ml of sample
with 10 ml of water.

Table12. Dissolution
S No Time minutes % Amount release Cumulative % Release
1 5 2 2
2 10 4 6
3 30 3 9
4 60 7 16
5 120 12 28
Page.35

Fig 4.Dissolution curve

5. Content Uniformity
In this test, 20 tablets were randomly selected and the percent drug content was determined, the
tablets contained not less than 85% or more than 115% of the labeled drug content can be
considered as the test was passed.
5. Assay
The drug content in each formulation was determined by triturating 20 tablets and powder
equivalent to average weight was added in 100ml of 0.1N Hydrochloric acid, followed by
stirring. The solution was filtered through a 0.45 membrane filter, diluted suitably and the
absorbance of resultant solution was measured spectrophotometrically at 315nm using 0.1 N
Hydrochloric acids as blank.
Page.36

CHAPTER VI
RESULTS
DISCUSSION
Page.37

RESULTS AND DISCUSSION

Ibuprofen is a non-steroidal anti-inflammatory agent belonging to the group of propanoic acid


derivatives. It shows a plasmatic half-life of 1.8-2.0 h; as a result it has to be administered 3 to 6
times a day, making this drug a suitable candidate for a controlled/sustained release formulation.
In this present study hydrophilic polyacrylate polymer such as eudragit (RS 100 & RL 100) and
the hydrophilic polymer of HPMC in different grades like HPMC K4M, K100M & K15M have
been employed to formulate sustained release tablets of ibuprofen in different batches The
sustained release tablets of ibuprofen were prepared (10 batches) by direct compression method
according to the formulae given in table 2. Direct compression is one of the techniques which
require the incorporation of directly compressible diluents into the formulation. It does not
require the use of water or heat the formula and is the ideal method for moisture and heat liable
medications. This is a process of compressing mixed powders into tablets without the need of
intermediate granulating step. This technique involves conventional equipment, commonly
available excipients and a limited number of processing steps. High doses can also be
accommodated, and the final weight of tablet can easily exceed than that of other methods.

Over the past few decades, significant medical advances have been made in the area of drug
delivery with the development of controlled release dosage forms. The primary benefit of a
sustained release dosage form in comparison with conventional dosage form, maintains uniform
drug plasma concentration over an extended period of time and hence the uniform therapeutic
effect is achieved. To get a successfully sustained release product, the drug must be released
from the dosage form at a predetermined rate and dissolve in the gastrointestinal fluids
Page.38

CONCLUSION

Sustained release systems include any drug delivery system that achieves slow release of drug
over an extended period of time. If the system is successful in maintaining constant drug levels
in the blood or target tissue it is considered as controlled release system. If it is unsuccessful at
this but nevertheless extends the duration of action over that achieved by conventional delivery,
it is considered a prolonged release system. The oral route of administration for sustained release
systems has received greater attention because of more flexibility in dosage form design. The
design of oral sustained release delivery systems is subject to several inter related variables of
considerable importance such as the type of delivery system, the disease being treated, the
patient, the length of therapy and the properties of the drug.
Ibuprofen is a nonsteroidal anti-inflammatory agent used extensively in the treatment of
rheumatoid arthritis, degenerative joint disease, osteoarthritis, ankylosing spondylitis, acute
musculoskeletal disorders, and low back pain.
Page.39

REFERENCES
.

1. Nalla C, Gopinath H, Debjit B, Williamkeri I and Reddy TA. Modified release dosage
forms. J Chem Pharm Sci, 2013; 6(1): 13-21.
2. Vyas, S.P., & Khar, R.K. (2002). Controlled Drug delivery: Concepts and Advances.
Concepts and Advances. Vallabh prakashan.
3. Remington, The Science and Practice of pharmacy, 20 th Edn, vol.I,
pg.no.903-913
4. Crank, J. (1975). The Mathematics of Diffusion. New York: Oxford Press
5. Kar RK, Mohapatra S and Barik BB. Design and characterization of controlled release
matrix tablets of Zidovudine. Asian J Pharm Cli Res, 2009; 2: 54.
6. Kumar S, Shashikant and Bharat P. Sustained release drug delivery system: a review. Int J
Inst Pharm Life Sci, 20122(3): 356-376.
7. Kumar S, Shashikant and Bharat P. Sustained release drug delivery system: a review. Int J
Inst Pharm Life Sci, 20122(3): 356-376.
8. Chugh I, Seth N, Rana AC and Gupta S. Oral sustained release drug delivery system: an
overview. Int Res J Pharm, 2012;3 (5): 57-62.
9. Bhargava A, Rathore RPS, Tanwar YS, Gupta S and Bhaduka G. Oral sustained release
dosage form: an opportunity to prolong the release of drug. Int J Adv Res Pharm Bio Sci,
3(1), 2013, 7-14
10. Thakor RS, Majmudar FD, Patel JK and Rajpit JC. Review: osmotic drug delivery
systems current scenario. J Pharm Res, 2010; 3(4):771-775.
11. Ratnaparkhi MP and Gupta JP, Sustained release oral drug delivery system - an overview.
Int J Pharm Res Rev, 2013; 2(3): 11-21.
Page.40

12. Shah N, Patel N, Patel KR and Patel D. A review on osmotically controlled oral drug
delivery systems. J Pharm Sci Bio Res, 2012;2(5): 230-237.
13. Thombre NA, Aher AS, Wadkar AV and Kshirsagar SJ. A review on sustained release oral
drug delivery system. Int J Pharm Res Sch, 2015; 4(2): 361-371.
14. Swabrick. J. & Boylan, J.C. (1996). Encyclopedia of pharmaceutical technology.
Newyork: Marcel Dekker.
15. Chauhan MJ and Patel SA. A concise review on sustained drug delivery system and its
opportunities. Am J Pharm Tech Res, 2012;2(2): 227-238
16. Allen, L.V., Popvich, G.N., & Ansel, H.C. (2004). Ansels Pharmaceutical dosage forms
and drug delivery system.
17. Kube RS, Kadam VS, Shendarkar GR, Jadhav SB and Bharkad VB. Sustained release
drug delivery system: review. Int J Res Pharm Biotech, 2015; 3(3) 246:-251.
18. Lapidus H and Lordi NG. Studies on controlled release formulations. J Pharm Sci, 1968;
57, 1292.

19. Anoop Kumar singh et al. Isolation, Characterization and formulation properties of a new
plant gum obtained from mangifera indica, Int J Pharm Biomed Res, 1(2), 2010, 35-41.

20. Banks Michael and E.alulton Michael, Fluidized-bed Granulation: A Chronology, DIP,
17(11), 1991, 1437- 1463.

21. Davies WK, Gloor WT, Batch production of pharmaceutical granulations in a fluidized
bed: Effects of process variables on physical properties of final granulation. Journal of
Pharmaceutical Sciences, 60(12), 1971, 1869- 1874.

22. Davies WL, Gloor WT. Batch production of pharmaceutical granulations in a fluidized
bed 2: effect of various binders and their concentrations on granulations and compressed
tablets. Journal of Pharmaceutical sciences 1972, 61(4), 1972, 618-622.
Page.41

23. Georgakopoulos PP, Malamataris S, Dolamidis G, The Effect of using different grades of
PVP and gelatin as binder in the fluidized bed granulation and tableting of lactose,
Pharmazie, 38(4), 1983, 240-243.

24. Girish K Jani, Dhiren P Shah, Vipul D Prajapati, Vineet C Jain. Gums and Mucilages,
AJPS, 4(5), 2009, 309-323.

25. Heng PWS, Roller compaction of crude plant material: Influence of process variables,
PVP and Comilling. Pharmaceutical Development and Technology, 9(2), 2004, 135-144.

26. Leon L, Herbert AL, Joseph LK, The theory and practice of industrial pharmacy, 3 rd ed.
Bombay, Varghese Publishing House, 1991.

27. Lowenthal W, Disintegration of tablets, Journal of Pharmaceutical Sciences, 61(11),


2006, 1695-1711.

28. Odeku OA, Itiola OA, Evaluation of the effects of khaya gum on the mechanical and
release properties of paracetamol tablets, DIP, 29(3); 2003, 311-320.

29. Pereira de Souza T et al. Eudragit E as excipient for production of granules and tablets
from phyllanthus niruri l spray-dried extract, AAPS Pharm Scitech, 8(2), 2007, A-34.

You might also like